Home › NDC Lookup › RxCUI directory › RxCUI 2288432

{4 (ozanimod 0.23 MG Oral Capsule) / 3 (ozanimod 0.46 MG Oral Capsule) } Pack — RxCUI 2288432

RxNorm drug concept · Generic pack
RxCUI 2288432 Generic pack · GPCK ● Current RxNorm concept 3 FDA products 5 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2288432
Official name{4 (ozanimod 0.23 MG Oral Capsule) / 3 (ozanimod 0.46 MG Oral Capsule) } Pack
Concept typeGeneric pack (GPCK)
RxNorm statusCurrent RxNorm concept
Also known asozanimod 7-Day Starter Pack
FDA products mapped3
Package NDCs mapped5
Reported Medicaid activity (SDUD)5,236 prescriptions · 30 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Ozanimod: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Zeposia is used for two different conditions. If you have relapsing multiple sclerosis — including relapsing-remitting MS or certain other active forms — it helps reduce the freque...
  • Zeposia can slow your heart rate a little when you first start it — that's just how this class of drug works. The 7-day gradual dose increase (called titration) is specifically des...
  • Why do I have to start with a lower dose and work my way up?
  • The most common ones are things like upper respiratory infections (colds, sore throat), headache, and slightly elevated liver numbers on blood tests — most people tolerate those re...
📖 Read our full Ozanimod guide →

🕸️ Concept Web — How {4 (ozanimod 0.23 MG Oral Capsule) / 3 (ozanimod... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept {4 (ozanimod 0.23 MG Oral Capsule) / 3 (ozanimod 0.46 MG Oral Capsule) } Pack RxCUI 2288432

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Ozanimod 2288236
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Zeposia 2288407
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Ozanimod Oral Capsule 2288405
    • Ozanimod Oral Product 2288403
    • Ozanimod Pill 2288404
    • Ozanimod Oral Capsule [Zeposia] 2288409
    • Zeposia Oral Product 2288410
    • Zeposia Pill 2288411
    • Pack 746839
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 8

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

  5. Packs 1

    Fixed collections of drugs packaged and sold together, like dose packs.

Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

Brand-Name Concepts

📦 FDA Products & Package NDCs

3 products · 5 package NDCs
5 package NDCs map to RxCUI 2288432 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
59572-0810-07 1 KIT in 1 BLISTER PACK (59572-810-07) * 1 CAPSULE in 1 BL... ZEPOSIA 7-Day Starter Pack Celgene Corporation 2020-03-27
59572-0810-97 1 KIT in 1 BLISTER PACK (59572-810-97) * 1 CAPSULE in 1 BL... ZEPOSIA 7-Day Starter Pack Celgene Corporation 2020-03-27
59572-0820-30 30 CAPSULE in 1 BOTTLE, PLASTIC (59572-820-30) ZEPOSIA Celgene Corporation 2020-03-27
59572-0890-28 1 KIT in 1 CARTON (59572-890-28) * 1 CAPSULE in 1 BLISTER... ZEPOSIA Starter Kit Celgene Corporation 2023-06-20
59572-0890-98 1 KIT in 1 CARTON (59572-890-98) * 1 CAPSULE in 1 BLISTER... ZEPOSIA Starter Kit Celgene Corporation 2023-06-20
Observed labelers: Celgene Corporation (5) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.